Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 14/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.34 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.32 |
| ▸ | PGK1 | P00558 | 1/20 | 0.32 |
| ▸ | PGK2 | P07205 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17143219 | 0.98 | FDPS (0.37) | FDPSLMNAGGPS1BBOX1PGK1 | |
| SCHEMBL1692406 | 0.84 | FDPS (0.52) | FDPSGGPS1 | |
| SCHEMBL23001058 | 0.81 | FDPS (0.48) | FDPSGGPS1 | |
| SCHEMBL23001100 | 0.80 | FDPS (0.45) | FDPSGGPS1BBOX1 | |
| SCHEMBL23001089 | 0.80 | FDPS (0.45) | FDPSGGPS1BBOX1 | |
| SCHEMBL252754 | 0.80 | FDPS (0.48) | FDPSLMNAGGPS1 | |
| SCHEMBL8160109 | 0.79 | FDPS (0.57) | FDPSGGPS1 | |
| SCHEMBL62052 | 0.78 | FDPS (0.58) | FDPSGGPS1 | |
| SCHEMBL905578 | 0.78 | FDPS (0.58) | FDPSGGPS1 | |
| SCHEMBL1044717 | 0.78 | FDPS (0.58) | FDPSGGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 998 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144751-A1 | LIPOSOME COMPOSITIONS COMPRISING WEAK ACID DRUGS AND USES THEREOF | PHARMOSA BIOPHARM INC. (TW) | 2026-05-28 | — | — | US | claimed |
| US-20260097095-A1 | PEGYLATED RECONSTITUTED HIGH-DENSITY LIPOPROTEIN NANOPARTICLES | MEPSGEN CO LTD (KR) | 2026-04-09 | — | — | US | claimed |
| US-20260069535-A1 | NEBULIZER KITS AND USES THEREOF | PHARMOSA BIOPHARM INC (TW) | 2026-03-12 | — | — | US | claimed |
| EP-4706644-A1 | RECONSTITUTED HIGH-DENSITY LIPOPROTEIN NANOPARTICLES COMPRISING CHOLESTEROL | Mepsgen Co., Ltd. (KR) | 2026-03-11 | — | — | EP | claimed |
| EP-4706645-A1 | PEGYLATED RECONSTITUTED HIGH-DENSITY LIPOPROTEIN NANOPARTICLES | Mepsgen Co., Ltd. (KR) | 2026-03-11 | — | — | EP | claimed |
| US-12551437-B2 | Liposome compositions comprising weak acid drugs and uses thereof | PHARMOSA BIOPHARM INC. (TW) | 2026-02-17 | — | — | US | claimed |
| EP-4691619-A1 | MICROFLUIDIC DEVICE FOR MANUFACTURING UNIFORM NANOPARTICLES | Mepsgen Co., Ltd. (KR) | 2026-02-11 | — | — | EP | claimed |
| US-20260021485-A1 | MICROFLUIDIC DEVICE FOR MANUFACTURING UNIFORM NANOPARTICLES | MEPSGEN CO LTD (KR) | 2026-01-22 | — | — | US | claimed |
| WO-2025230917-A1 | METHODS FOR TREATING SYSTEMIC SCLEROSIS AND FROST BITE BY INHALATION THERAPY | PHARMOSA BIOPHARM INC. (TW) | 2025-11-06 | — | — | WO | claimed |
| US-20250288688-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | RECODE THERAPEUTICS, INC. | 2025-09-18 | — | — | US | claimed |
| EP-1626728-A2 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | Vascular Biogenics Ltd. (IL) | 2006-02-22 | — | — | EP | claimed |
| WO-2006006161-A2 | IMPROVED PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | VASCULAR BIOGENICS LTD. (IL) | 2006-01-19 | — | — | WO | claimed |
| US-20050107287-A1 | Treatment of cancers by inhalation of stable platinum-containing formulations | PILKIEWICZ FRANK G (US) | 2005-05-19 | — | — | US | claimed |
| EP-1305322-A4 | DERIVATIVES OF BRANCHED-CHAIN LIPOPHILIC MOLECULES AND USES THEREOF | DPHARM LTD (IL) | 2005-04-13 | — | — | EP | claimed |
| WO-2004106486-A2 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | VASCULAR BIOGENICS LTD. (IL) | 2004-12-09 | — | — | WO | claimed |
| JP-2004505898-A | — | — | 2004-02-26 | — | — | JP | claimed |
| EP-1305322-A2 | DERIVATIVES OF BRANCHED-CHAIN LIPOPHILIC MOLECULES AND USES THEREOF | D-Pharm Ltd. (IL) | 2003-05-02 | — | — | EP | claimed |
| WO-2002011666-A2 | DERIVATIVES OF BRANCHED-CHAIN LIPOPHILIC MOLECULES AND USES THEREOF | D-PHARM LTD. (IL) | 2002-02-14 | — | — | WO | claimed |
| EP-1049491-A1 | GENE THERAPY OF TUMORS USING NON-VIRAL DELIVERY SYSTEM | Perez-Soler, Roman (US) | 2000-11-08 | — | — | EP | claimed |
| WO-1999034835-A1 | GENE THERAPY OF TUMORS USING NON-VIRAL DELIVERY SYSTEM | PEREZ SOLER ROMAN (US) | 1999-07-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288688-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | LIPA, AUP1, PLIN3 | FDPS 451/4885LMNA 665/4885GGPS1 207/4885 |
| US-20260021485-A1 | MICROFLUIDIC DEVICE FOR MANUFACTURING UNIFORM NANOPARTICLES | CD44, CAD, SLCO4C1 | FDPS 942/4885LMNA 3354/4885GGPS1 3854/4885 |
| US-20260069535-A1 | NEBULIZER KITS AND USES THEREOF | PTGER2, PTGER1, PTGIR | FDPS 1727/4885LMNA 2537/4885GGPS1 391/4885 |
| US-20260144751-A1 | LIPOSOME COMPOSITIONS COMPRISING WEAK ACID DRUGS AND USES THEREOF | LIPA, NSF, SLC26A3 | FDPS 2793/4885LMNA 1501/4885GGPS1 1728/4885 |
| US-20260097095-A1 | PEGYLATED RECONSTITUTED HIGH-DENSITY LIPOPROTEIN NANOPARTICLES | LDLR, CETP, APOL1 | FDPS 2752/4885LMNA 2329/4885GGPS1 3377/4885 |
| US-12551437-B2 | Liposome compositions comprising weak acid drugs and uses thereof | SLC26A3, LIPA, NSF | FDPS 2560/4885LMNA 2676/4885GGPS1 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.